In short
This article discusses a clinical trial investigating the use of UCPVax, a CD4 Th1-inducer cancer vaccine derived from telomerase, in combination with atezolizumab and bevacizumab for patients with unresectable hepatocellular carcinoma (liver cancer). The study aims to assess the efficacy and safety of this combination therapy compared to standard treatment, focusing on objective response rates, overall survival, and quality of life improvements.
At a glance
- Study Type
- Phase II randomized clinical trial
- Condition
- Unresectable hepatocellular carcinoma (liver cancer)
- Intervention
- UCPVax + Atezolizumab + Bevacizumab vs. Atezolizumab + Bevacizumab
- Primary Outcome
- Objective response rate at 6 months
- Key Secondary Outcomes
- Overall survival, progression-free survival, quality of life
- Eligibility
- Adults with confirmed unresectable HCC, no prior systemic treatment
- Treatment Duration
- Up to 12 months for UCPVax
- Biomarker Analysis
- TERT promoter mutations, telomerase expression, PD-L1 expression
What is UCP4?
UCP4 is an experimental cancer vaccine being studied for the treatment of advanced liver cancer. It is also known by the name UCPVax. UCP4 is a type of immunotherapy, which means it works by helping the body's own immune system fight cancer cells.
How does UCP4 work?
UCP4 is designed to stimulate a specific type of immune cell called CD4 T helper 1 (Th1) cells. These cells play an important role in the immune response against cancer. The vaccine is made from a part of an enzyme called telomerase, which is often overactive in cancer cells. By targeting telomerase, UCP4 aims to help the immune system recognize and attack cancer cells more effectively.
What conditions does UCP4 treat?
UCP4 is currently being studied for the treatment of hepatocellular carcinoma (HCC), which is the most common type of primary liver cancer. Specifically, it is being tested in patients with:
- Locally advanced HCC (cancer that has spread within the liver but not to other parts of the body)
- Metastatic HCC (cancer that has spread to other parts of the body)
- Unresectable HCC (cancer that cannot be removed by surgery)
Current research on UCP4
UCP4 is currently being studied in a phase II clinical trial. This trial is testing UCP4 in combination with two other drugs:
- Atezolizumab: An immunotherapy drug that helps the immune system attack cancer cells
- Bevacizumab: A drug that helps prevent the growth of new blood vessels that feed tumors
The main goal of this study is to see if adding UCP4 to atezolizumab and bevacizumab can improve the response rate in patients with unresectable liver cancer.
Potential benefits of UCP4
Researchers are hoping that UCP4, when combined with other treatments, may offer several potential benefits for patients with advanced liver cancer:
- Improved tumor response rates
- Longer survival times
- Delayed disease progression
- Better quality of life
However, it's important to note that these potential benefits are still being studied and are not yet proven.
Who may be eligible for UCP4 treatment?
The current clinical trial for UCP4 has specific criteria for who can participate. Some key factors include:
- Patients must have confirmed hepatocellular carcinoma that is locally advanced, metastatic, or unresectable
- Patients should not have received previous systemic anti-cancer treatment
- Patients must be at least 18 years old
- Patients must have good overall health status and liver function
There are also several factors that may exclude patients from participating, such as certain medical conditions or previous treatments.
Safety and side effects
As UCP4 is still in the research phase, its full safety profile is not yet known. The current clinical trial is evaluating the safety of UCP4 when used in combination with atezolizumab and bevacizumab. Patients in the trial will be closely monitored for any side effects or adverse reactions.
It's important to remember that UCP4 is an experimental treatment and is not yet approved for general use. Patients interested in this treatment should discuss it with their healthcare provider and consider participating in clinical trials if eligible.